Skip to main content

AMG 510 in NSCLC

This trial is investigating the safety and efficacy of AMG 510 – an agent targeting KRAS – in patients with advanced solid tumors harboring a KRAS G12C mutation.

Phase I trial results

AMG 510 has demonstrated promising efficacy and tolerability in previously treated patients with locally advanced or metastatic KRAS-mutated non-small-cell lung cancer.

Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the trial and the next steps for the research (5:34):

Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019: